In the intervention group of 357 patients, 27 had additional removal of residual tumor based on imaging agent-guided technology. Six of 357 patients had adverse events and no deaths were reported in this trial. The Latest A recent multi-center phase 3 clinical trial funded by Lumicell investigated the safety and efficacy of LUM Imaging System
Gene therapy demonstrated clinically meaningful vision improvement in legally blind individuals. The therapy is capable of restoring vision even in advanced disease stages. The Latest A recent two-year phase 2b, randomized, double-masked, sham-controlled multicenter clinical trial by Boyer et al. and Nanoscope Therapeutics investigated mutation-agnostic gene therapy for the treatment of permanent and severe
Doctors at the Maisonneuve Rosemont ophthamology clinic performed groundbreaking surgery on an 11-year-old boy, reversing a rare genetic condition that can cause blindness.